: Conduct regular ECGs to monitor for potential proarrhythmic effects or excessive QT prolongation.
Clinicians should monitor several factors to prevent adverse outcomes: ATHENA HEART [310]
: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III). : Conduct regular ECGs to monitor for potential
Patients with paroxysmal or persistent AF or AFL who are in sinus rhythm or who will be cardioverted. ATHENA HEART [310]
The official FDA label outlines critical safety measures based on ATHENA data: :
It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications
The ATHENA trial was a landmark study that evaluated the efficacy of dronedarone in reducing cardiovascular hospitalizations or death.